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for Essential Health Benefits (EHBs). Primary discussions with US private payers 
and ex-CMS policy experts were conducted to understand key issues for medical 
products. RESULTS: The ACA has introduced major changes for product pricing, 
deductible, coverage and uptake. For pricing, major changes are a 50% discount for 
Part D population and an increased rebate of 23.1% for the Medicaid population. 
For deductibles, the patient costs are capped at $12,700. For uptake, an additional 
population is eligible based on expanded access to 30 million uninsured Americans, 
with more than half of them being under the age of 35 years (~59%). For access, 
the 2014 definition of Essential Drug Benefits is likely to either expand or reduce 
coverage depending upon the state and class of drugs. For example, for NSAIDs 
in CA only 20 drugs are covered, while in NY, 40 drugs are covered. During 2012-
2014 Accountable Care Organizations (ACOs) have increased to ~600 organizations 
covering ~18 million lives, which has created a new stakeholder of an integrated 
provider-payer partnership. CONCLUSIONS: ACA has introduced major changes 
which will have a significant impact on converge, pricing and access of pharma-
ceutical and device products.
PHP106
Are eU PAyers AdAPting BiosimilAr Pricing And reimBUrsement 
APProvAl Processes to oPtimize HeAltHcAre sAvings?
Foxon G.1, Fox G.1, Craddy P.2
1Remap Consulting, Cheshire, UK, 2Remap Consulting, Bern, Switzerland
OBJECTIVES: Determine if EU pricing and reimbursement (P&R) bodies have revised 
their P&R approval processes for biosimilar medicines to enable faster access and 
optimize the potential healthcare savings. This study analyzed the biosimilar P&R 
procedures across Europe to determine how these differed to the standard and 
generic P&R approval processes. METHODS: OECD pharmaceutical spend data 
across Europe was utilized to identify the European countries that account for 90% 
of EU pharmaceutical spend. The official P&R websites for these 12 countries (France, 
Germany, Italy, Spain, UK, Austria, Poland, Belgium, Netherlands, Sweden, Greece, 
and Switzerland) were identified and analyzed to determine if biosimilar P&R pro-
cess followed the standard, generic or a specific biosimilar P&R approval process. If 
no biosimilar P&R documents were identified, the inference was that they follow the 
standard P&R approval process. RESULTS: Of the 12 countries reviewed, 8 require 
biosimilars to undergo the full standard P&R process, often requiring submission 
of comparative clinical data and development of health economic and/or budget 
impact models. In addition, Switzerland and Spain mandated an additional bio-
similar price discount be applied. 3 markets applied the generic approval process 
to biosimilars, enabling faster access to market. Italy was the only country having a 
specific, abridged biosimilar P&R pathway, where faster access to market is achieved 
if a pre-specified biosimilar price discount, dependent on the sales of the reference 
product, is applied. CONCLUSIONS: In the majority of European countries biosimi-
lars, unlike generics, are still required to undergo a comprehensive standard P&R 
process. Such processes are time consuming, resource intensive and costly for both 
the manufacturers and P&R bodies. The implication is that European payers have 
yet to consider biosimilars to be clinically comparable to their reference products 
or to fully recognise the potential healthcare savings from having an expedited 
biosimilar P&R approval process.
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OBJECTIVES: World Health Organisation (WHO)-CHOICE promotes a threshold 
defined as three times (3x) gross domestic product (GDP) per capita as a guide to deter-
mining cost-effectiveness of health interventions. This analysis sought to evaluate 
the stability of the 3x threshold over time for different countries and the implications 
of this for frequency of requirements to update the threshold value. METHODS: GDP 
per capita data from 2000 to 2014 were taken from the International Monetary Fund 
dataset and used to calculate 3x thresholds for a range of countries considered to be 
representative of different sizes of economies and levels of economic development. 
Proportional changes in the 3x threshold across the entire period and on a year-by-
year basis were analyzed, and time to doubling (and increase by other magnitudes) 
of the initial cost-effectiveness threshold was explored. RESULTS: The 3x threshold 
has increased over the period 2000 to 2014 for 99% of all countries analyzed. The 
average proportional increase in the 3x threshold over this period varied consid-
erably by country, with Belarus having the highest proportional increase over the 
entire time period (94 times). Time to doubling of the 3x threshold was highly variable 
(range 2.1 – 450 years [median 9.1 years]) and was as low as 2 – 3 years for a number 
of countries. High levels of variability were observed between countries within the 
same WHO country groupings. CONCLUSIONS: The results suggest that considerable 
proportional changes to the value of the 3x threshold are observed for a number of 
countries over the short-term. For some countries, the cost-effectiveness threshold 
would be expected to increase dramatically even over a yearly timescale. This research 
highlights the need for countries looking to adopt this threshold to carefully consider 
requirements for updating the threshold and for managing the impact of this, for 
instance in relation to incentives for delayed pharmaceutical entry.
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OBJECTIVES: The objectives of this study were to examine the potential barriers 
to new drug accessibility by exploring factors associated with the marketing lag 
and reimbursement lag, and comparing Taiwan’s approval lag with selected coun-
tries. METHODS: This study focused on new drugs reviewed by Taiwan’s NHI Drug 
Review Committee (DRC) from March, 2001 to December, 2012. Linear regression 
was adopted to estimate factors associated with the marketing lag. A two-part 
drugs at BRL 61 million. CONCLUSIONS: The responsible use of OTC medicines 
can reduce up to 21% the volume of emergency attendances, and for every BRL 1 
spent with OTC drugs is equivalent to an economy of BRL 7 in the public health 
system by reducing emergency visits and improductible days. The self-care, if done 
properly, can be an important factor in the improvement of public health, increas-
ing productivity and reducing costs, in addition to providing more time for health 
professionals in the care of more complex cases. Notwithstanding the expansion 
of OTC drugs usage should be conducted responsibly with quality products and 
effective pharmaceutical care.
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BACKGROUND: Prescription medication adherence is a known health related bar-
rier for elderly patients, leading to insufficient disease control and negative health 
outcomes. Many barriers to prescription adherence have been identified in the litera-
ture, but it is unclear what barriers physicians feel most strongly inhibit adherence 
among patients enrolled in Medicare Advantage Part D (MAPD) plans. OBJECTIVES: 
To identify physician perceived barriers to medication adherence among MAPD 
patients. METHODS: A survey was developed and administered to primary care 
physicians (PCPs) contracted within a MAPD plan in Texas. Surveys were distributed 
during an all-PCP quarterly meeting to increase completion and return rates, and 
were collected prior to the meeting’s conclusion. A free response section was utilized 
for PCPs to indicate up to 3 of the top barriers to medication adherence that they feel 
impact their MAPD patients. Responses were categorized into 8 distinct groups (cost, 
side effects, formulary, lack of patient understanding, forgetfulness, transportation, 
dosage changes, and other). The “other” category encompassed cultural issues, lan-
guage barriers, obtaining drugs out of the country or not using an insurance card, 
and problems at the pharmacy. RESULTS: A total of 210 PCPs (68%) across Texas 
completed and returned the survey. Cost was by far the most commonly identified 
barrier, reported by 77% of respondents. Patient understanding was also a big concern, 
identified by 53% of PCPs. Only 18% of PCPs indicated side effects (actual or potential) 
as a top barrier. Forgetfulness was cited by 22% of PCPs and transportation by 14%. 
Twenty percent of PCP responses fell within the “other” category defined above, while 
formulary (10%) and dosage change (2%) were the least frequently mentioned bar-
riers. CONCLUSIONS: MAPD PCPs most frequently cite financial issues and lack of 
patient understanding as reasons for non-adherence in their patients.
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OBJECTIVES: High risk medication (HRM) use in the elderly is a quality measure 
that contributes to the CMS Star Rating. Various clinical programs to target HRM 
have been described; however, the impact of interventions among the dual eligible 
(DE) Medicare Advantage population is unknown. The objective of this study is to 
compare the impact of a faxed alert intervention directed at HRMs between DE 
and non-DE Medicare Advantage beneficiaries. METHODS: This was a retrospective 
study of pharmacy claims data among Medicare Advantage beneficiaries > 65 years 
of age in 2014. HRMs were defined by industry standard of the American Geriatric 
Society Beers Criteria for Potentially Inappropriate Medication use in Older Adults. 
The HRM Avoidance Program alerts the prescribing provider via fax regarding the 
HRM with recommended alternative(s). Eligible interventions were identified by the 
first HRM fill in the calendar year. Intervention success was defined when a recom-
mended alternative medication was subsequently filled and/or no subsequent fill 
for the same HRM occurred for > 3 months from the index claim date. RESULTS: 
This data represents 926,585 non-DE and 178,840 DE Medicare Advantage benefi-
ciaries. A total of 127,900 pharmacy claims were eligible for the HRM Avoidance 
Program. Of these, 113,627 (89%) were among non-DE and 14,273 (11%) were among 
DE Medicare beneficiaries. The HRM Avoidance Program was successful among 
42% of non-DE compared to 44% of the DE Medicare beneficiaries receiving the 
intervention (p< 0.0001). Significantly higher success rates were observed among 
DE compared to non-DE beneficiaries with the following medication claims: butal-
bital (p= 0.005), carisprodal (p< 0.0001), cyclobenzaprine (p< 0.0001), estrogens 
(p= 0.003), indomethocin (p= 0.001), methocarbamol (p< 0.0001), and promethazine 
(p< 0.0001). CONCLUSIONS: The fax interventions targeting HRM was more success-
ful in the DE than the non-DE Medicare Advantage population. However, further 
research is needed to understand the factors behind the difference in success for 
these populations.
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OBJECTIVES: The Affordable Care Act (ACA) has introduced several major changes 
which can impact product pricing, access and uptake in the United States. The 
objective of this analysis was to review all major new changes due to ACA and 
develop implications for market access for medical products. METHODS: The new 
pricing, access and coverage changes impacting the pharmaceutical and devices 
products were reviewed using the bill for ACA (H. R. 3590), 2011-2013 policy publica-
tions, reports by the Congressional Budget Office and Government Accountability 
Office, and the latest Centers for Medicare & Medicaid Services (CMS) guidelines 
